Strong dose from Dr. Reddy’s - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Strong dose from Dr. Reddy’s

Dec 14, 1999

Cheminor Drugs (Cheminor) part of the Dr. Reddy’s group is likely to assume full control of its US venture Reddy Cheminor Inc by acquiring the 25% holding of its US partner. So far Cheminor has been the main supplier of bulk drugs to Dr. Reddy’s Laboratories (DRL). The move will come ahead of the merger in India between Cheminor and DRL, which is likely to happen in the next financial year.

Another impending merger is that of American Remedies (ARL) with DRL. The latter acquired a 45% stake in ARL and has already acquired a further 15-20% stake from the associates of ARL’s promoters. An open offer for to acquire another 20% from the company’s shareholders is slated to open in January 2000.

Cheminor has filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline. The company has set a target to file three to five ANDAs every year and have already received approval for ranitidine (75 mg), the anti–ulcerant omeprazole and anti-depressant fluoxetine.

Cheminor has also been proactive on another plane viz. in filing suits challenging the existing product patent of the patent holders. Reddy Cheminor has filed patent suits against multinational giants Astra Zeneca (producer of omeprazole), Bayer (ciprofloxacin) and Eli Lilly (fluoxetine).

As per the US law, if successful, the company filing the first case gets a six–month period of exclusivity while marketing its generic. Simply put, this means it can charge prices in the range of 50% of the branded product, rather than 10–30% when it has to compete with other generics.

Meanwhile DRL itself has three new original molecules in its research pipeline. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future.

Any deal DRL enters into is likely to be modelled along the line sit has with the Danish company Novo Nordisk which is developing DRL’s diabetes lead molecules. The company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

Equitymaster requests your view! Post a comment on "Strong dose from Dr. Reddy’s". Click here!


More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This... (Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


  • Track your investment in CHEMINOR DRUGS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks